List of Excipients in Branded Drug LYVISPAH

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals LLC	LYVISPAH	baclofen	64896-076	CALCIUM STEARATE
Amneal Pharmaceuticals LLC	LYVISPAH	baclofen	64896-076	CROSPOVIDONE
Amneal Pharmaceuticals LLC	LYVISPAH	baclofen	64896-076	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Amneal Pharmaceuticals LLC	LYVISPAH	baclofen	64896-076	HYPROMELLOSES
Amneal Pharmaceuticals LLC	LYVISPAH	baclofen	64896-076	MANNITOL

LYVISPAH Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

LYVISPAH is a prescription baclofen oral granule product designed for patients who have difficulty swallowing conventional tablets. Its commercial value rests on formulation convenience rather than a new active ingredient: single-dose packets, oral-granule administration, multiple strengths, and administration with soft food or liquids. The core excipient strategy is simple and low-cost, but opportunities remain in taste masking, pediatric acceptability, dose flexibility, packaging, and differentiated alternate versions.

What is LYVISPAH and how is it administered?

LYVISPAH contains baclofen, a gamma-aminobutyric acid type B receptor agonist used to treat spasticity associated with multiple sclerosis, spinal cord disease, and other neurologic conditions.[1]

Attribute	LYVISPAH
Active ingredient	Baclofen
Dosage form	Oral granules
Strengths	5 mg, 10 mg, and 20 mg
Route	Oral
Indication	Spasticity
Administration	Direct oral administration or mixing with liquids and soft foods
U.S. regulatory pathway	NDA
Applicant	Granules Pharmaceuticals, Inc.
FDA approval	December 2021
Product category	Nonbiologic prescription drug

The product is intended for patients who cannot reliably swallow tablets. The granules may be administered directly into the mouth or mixed with water, juice, soft food, or other compatible vehicles under the product instructions.[1]

The formulation does not create a new pharmacologic mechanism. Its differentiation is based on dosage form, administration flexibility, and potential adherence benefits.

What excipients are used in LYVISPAH?

The publicly listed inactive ingredients are mannitol, sucralose, strawberry flavor, and colloidal silicon dioxide.[1]

Excipient	Likely formulation role	Commercial relevance
Mannitol	Bulking agent, carrier, mouthfeel modifier	Supports acceptable granule mass and a cooling oral sensation
Sucralose	High-intensity sweetener	Reduces perceived bitterness from baclofen
Strawberry flavor	Taste and aroma masking	Improves patient acceptability and supports pediatric-style positioning
Colloidal silicon dioxide	Glidant and flow aid	Supports powder handling, granulation, and dose uniformity

The excipient system is intentionally compact. It avoids complex polymers, preservatives, dyes, and high-cost lipid or multiparticulate technologies. That structure can reduce raw-material cost and simplify regulatory control, but it also limits differentiation from future baclofen granule products.

Mannitol as the principal bulking excipient

Mannitol is commercially attractive for oral granules because it is widely available, chemically stable, relatively low in hygroscopicity, and compatible with direct oral administration. Its cooling sensation can improve mouthfeel in some formulations, although that effect can become undesirable if the flavor system is weak.

Mannitol also supports low-density granule formation. The developer must control particle size, moisture, and compressibility because variation in those parameters can affect packet fill weight, segregation, dissolution, and dose uniformity.

Potential replacement or enhancement strategies include:

• Lactitol or sorbitol for different mouthfeel and solubility profiles.
• Isomalt for lower hygroscopicity and improved oral texture.
• Mannitol grades with different particle-size distributions.
• Co-processed mannitol systems to improve flow and reduce segregation.
• Low-moisture carriers for improved stability in stick-pack formats.

Any substitution would require comparative evaluation of dissolution, assay, content uniformity, powder flow, taste, and stability.

Sucralose and baclofen taste masking

Baclofen has a bitter taste that can be clinically relevant when the product is administered directly into the mouth. Sucralose is used as the primary sweetener in LYVISPAH, while strawberry flavor provides a recognizable taste profile.

Sucralose alone may not fully mask baclofen bitterness, particularly at the 20 mg strength or when the granules remain in the oral cavity. Commercial opportunities include:

• Higher-performance flavor systems.
• Sweetener combinations using acesulfame potassium, steviol glycosides, or thaumatin.
• Ion-exchange resin complexes.
• Lipid or polymeric taste-masking coatings.
• Microencapsulation of baclofen particles.
• pH-modified granules that reduce bitter taste release.
• Granules designed for rapid swallowing with limited oral residence time.

Taste masking must not materially delay baclofen release or create dose nonuniformity. A coating-based approach can also increase manufacturing complexity and may introduce new dissolution specifications.

Colloidal silicon dioxide and powder performance

Colloidal silicon dioxide is commonly used to improve flow and reduce cohesion in fine powders. Its role is important in a packet product because poor flow can cause variable fill weights and inconsistent unit-dose performance.

Commercially relevant formulation work includes optimizing:

• Silicon dioxide concentration.
• Surface area and grade.
• Granule porosity.
• Residual moisture.
• Electrostatic behavior.
• Segregation during transport.
• Compatibility with automated packet filling.

A competing product that maintains equivalent dissolution and dose uniformity with less glidant may have a cost advantage. A product requiring more sophisticated flow aids may gain manufacturing robustness but lose margin.

What commercial opportunities exist for LYVISPAH excipients?

The strongest opportunities are in patient acceptability, administration flexibility, and product extensions. The base excipient system is inexpensive and familiar, so value creation depends on improving use characteristics rather than simply changing inactive ingredients.

Pediatric and adolescent formulations

Baclofen is used in pediatric spasticity practice, although the approved labeling and evidence base must be distinguished from off-label use. A better-tasting granule could support use in children who cannot swallow tablets.

Potential product concepts include:

• Smaller packets for weight-based dosing.
• Lower-dose granules below 5 mg.
• Graduated multidose bottles.
• Flavor options beyond strawberry.
• Granules optimized for yogurt, applesauce, or juice.
• Reduced-sugar systems for chronic use.
• Unit doses packaged for school, clinic, or caregiver administration.

A pediatric formulation would need careful evaluation of excipient exposure, especially sweeteners, flavoring agents, and any new taste-masking polymers. FDA expects inactive ingredients in pediatric products to be justified for safety and acceptability.[2]

Dysphagia and neurologic-care positioning**

Patients with multiple sclerosis, spinal cord injury, stroke-related disability, cerebral palsy, and other neurologic conditions may have swallowing limitations. LYVISPAH directly addresses that administration barrier.

The commercial opportunity is strongest where caregivers administer chronic medication. Useful product attributes include:

• Clear mixing instructions.
• Rapid dispersion without clumping.
• Compatibility with common soft foods.
• Low residue in oral syringes or feeding tubes where permitted by labeling.
• Easy-open packets.
• Tactile and large-print packaging.
• Unit-dose portability.

Tube administration creates a separate regulatory and technical question. A formulation suitable for oral ingestion is not automatically suitable for enteral tubes. Device compatibility, adsorption, obstruction risk, flush volume, and dose recovery would require formal testing before commercial claims.

Single-dose packaging and adherence**

Unit-dose packets can reduce measuring errors and support caregiver administration. They also create packaging costs and a larger material footprint than bottles.

Potential packaging improvements include:

• Child-resistant cartons with accessible individual packets.
• Calendarized adherence packs.
• High-barrier laminate for moisture protection.
• Tear-open packets for patients with limited dexterity.
• Braille or tactile strength identification.
• Hospital and long-term-care bulk configurations.

The package is part of the product’s commercial differentiation. A low-cost generic may reproduce the formulation but provide inferior usability if it uses difficult-to-open sachets or lacks strength differentiation.

How does LYVISPAH compare with baclofen tablets and liquid products?

Product type	Administration advantage	Excipient opportunity	Main limitation
Baclofen tablets	Low cost, established supply	Conventional fillers, binders, disintegrants	Swallowing difficulty
Baclofen oral granules	Flexible administration and unit dosing	Taste masking, flow control, food compatibility	Higher packaging and manufacturing cost
Baclofen oral solution	Easy dose measurement and swallowing	Sweeteners, preservatives, viscosity modifiers	Stability, measuring errors, larger package volume
Intrathecal baclofen	Targeted delivery for severe spasticity	Sterile formulation and container system	Pump implantation and specialist care

LYVISPAH competes primarily against low-cost tablets and compounded or commercial liquid preparations. Its price premium must be supported by adherence, caregiver convenience, reduced administration errors, or access in patients unable to use tablets.

A liquid competitor may offer easier dose titration, but it introduces microbial, preservative, taste, viscosity, and spill-control issues. Granules can provide a more stable solid-state product while preserving administration flexibility.

What patents and regulatory exclusivity protect LYVISPAH?

LYVISPAH received FDA approval in December 2021 under NDA 215039.[3] As a new dosage form containing an established active ingredient, the product was eligible for three years of approval-related exclusivity under the Hatch-Waxman framework, assuming the approval relied on investigations essential to approval.[4]

That three-year period would generally have expired in December 2024. The exclusivity period does not prevent all later applications in the same therapeutic category, but it can restrict approval of certain abbreviated applications that rely on the protected clinical investigations during the exclusivity window.

Orange Book status

The FDA Orange Book is the controlling source for listed patents, exclusivity, and approved product information.[5] For LYVISPAH, commercial diligence should distinguish among:

1. FDA regulatory exclusivity.
2. Orange Book-listed patents, if any.
3. Unlisted formulation, manufacturing, packaging, or trade-secret rights.
4. Trademark protection for the LYVISPAH name.
5. Regulatory barriers associated with a different dosage form.

A formulation patent could potentially cover granule composition, particle architecture, taste masking, administration with food, or manufacturing conditions. A method-of-use patent could address treatment of a defined spasticity population or a specific administration protocol. Those claims would need to be assessed claim by claim rather than inferred from the product’s approval.

Paragraph IV and generic entry

A baclofen oral-granule competitor could pursue an ANDA if it can establish the required pharmaceutical equivalence and bioequivalence. The main technical risks are:

• Demonstrating equivalent baclofen release.
• Matching granule size and dose uniformity.
• Establishing bioequivalence despite food or vehicle administration.
• Reproducing taste and physical properties where relevant.
• Addressing any Orange Book-listed patents through certification.
• Avoiding formulation claims that are difficult to design around.

A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman process if an eligible patent is listed. No biosimilar pathway applies because baclofen is a synthetic small molecule, not a biologic.

How strong is the LYVISPAH patent estate?

The commercial strength of the estate depends on whether enforceable claims cover the granule architecture or only broad formulation concepts. A narrow patent covering a specific sweetener-flavor combination may be easy to design around. A patent covering particle coating, dose uniformity, dissolution behavior, and administration with specified vehicles would present a stronger barrier.

Patent layer	Potential protection	Generic vulnerability
Composition	Baclofen plus carrier and sweetener	High if excipients can be substituted
Granule structure	Particle size, coating, porosity, or release profile	Moderate if analytical equivalence is difficult
Taste masking	Encapsulation, resin complex, or coating	Moderate to high depending on claim breadth
Manufacturing	Granulation, drying, blending, or filling process	Often difficult to enforce against an undisclosed process
Method of use	Administration to defined spasticity patients	Limited if product label does not induce infringement
Packaging	Moisture barrier and unit-dose configuration	Usually weak unless tightly claimed

The most durable protection would normally come from a combination of composition, process, and device or packaging claims. A product relying mainly on conventional mannitol, sucralose, flavor, and colloidal silicon dioxide has a potentially manageable design-around pathway unless additional formulation claims exist.

What manufacturing and IP barriers affect commercial entry?

The active ingredient is widely established, so the primary barriers are dosage-form execution and regulatory equivalence.

Manufacturing controls should address:

• Baclofen distribution throughout the granule population.
• Segregation between active and excipients.
• Moisture uptake.
• Granule friability.
• Packet fill accuracy.
• Flavor uniformity.
• Dissolution after mixing with permitted vehicles.
• Stability under temperature and humidity stress.
• Cross-contamination control for potent powder handling.

Mannitol and colloidal silicon dioxide are available from multiple suppliers, which reduces supply-chain exclusivity. Flavor systems may create more practical differentiation because proprietary flavor compositions and supplier know-how can be difficult to replicate, even when they are not strong patent barriers.

A company seeking entry could use a different sweetener, alternative flavor, or coated baclofen particle. The regulatory burden would rise if the new formulation changes dissolution, pharmacokinetics, food effects, or administration instructions.

What licensing and partnership opportunities exist?

The most credible licensing opportunities are not based on baclofen itself. They involve enabling technologies and commercial channels.

Potential partners include:

• Taste-masking technology companies.
• Pediatric drug-delivery specialists.
• Contract manufacturers with sachet-filling capacity.
• Specialty pharmacies serving neurologic patients.
• Long-term-care pharmacy suppliers.
• Home-health and caregiver distribution networks.
• Companies with enteral-delivery compatibility platforms.

A licensee could improve LYVISPAH or launch a competing product through a formulation patent, development partnership, regional commercialization agreement, or contract-manufacturing arrangement. Public sources do not establish a material licensing transaction specific to LYVISPAH. Product ownership, distribution rights, and any private commercial agreement should not be inferred from the FDA approval record.

What revenue exposure and competitive risks exist?

Publicly available FDA materials do not disclose LYVISPAH product revenue. Revenue exposure depends on prescription volume, payer coverage, net price, and the share of baclofen users who need a non-tablet dosage form.

The principal competitive risks are:

• Generic baclofen tablets retaining a substantial price advantage.
• Compounded baclofen liquids serving patients with swallowing difficulties.
• Alternative oral liquids with easier dose titration.
• Intrathecal baclofen for severe, refractory spasticity.
• Generic oral granules entering after regulatory and patent barriers expire.
• Payer refusal to reimburse a premium dosage form.
• Limited prescriber awareness of administration advantages.

The commercial thesis is stronger in institutional, pediatric, and caregiver-administered settings than in routine adult patients who can swallow tablets.

What generic launch scenarios exist for LYVISPAH?

Scenario 1: Direct oral-granule ANDA

A competitor matches the 5 mg, 10 mg, and 20 mg strengths and uses a similar low-complexity excipient system. This is the most direct price threat if no blocking patent remains.

Scenario 2: Formulation design-around

A competitor uses a different carrier, sweetener, or flavor and supports approval with pharmaceutical equivalence and bioequivalence data. This approach may avoid narrow composition claims but can create new taste and dissolution development risk.

Scenario 3: Alternative dosage-form competition

A manufacturer launches a baclofen oral solution or a different sprinkle product. This would compete for the same dysphagia and caregiver populations without necessarily being therapeutically identical to LYVISPAH.

Scenario 4: Specialty-channel defense

The product maintains commercial protection through pediatric access, specialty pharmacy distribution, packaging convenience, and prescriber familiarity rather than patent exclusivity alone.

Key Takeaways

• LYVISPAH is a baclofen oral granule product approved by FDA in December 2021.
• Its listed excipients are mannitol, sucralose, strawberry flavor, and colloidal silicon dioxide.
• The excipient system supports bulking, sweetening, flavor masking, and powder flow.
• The strongest commercial opportunities are pediatric dosing, dysphagia care, caregiver administration, and unit-dose packaging.
• Taste masking and vehicle compatibility are the main technical areas for product differentiation.
• The three-year approval-related exclusivity period would generally have expired in December 2024.
• Baclofen has no biosimilar risk because it is a synthetic small molecule.
• Direct generic entry depends on Orange Book patents, ANDA strategy, bioequivalence, and formulation design-around feasibility.
• Public FDA materials do not disclose LYVISPAH revenue or a product-specific licensing transaction.
• The product’s defensibility is likely to depend more on formulation execution, packaging, and channel strategy than on the established baclofen active ingredient.

FAQs

Can LYVISPAH excipients be substituted in a generic product?

Yes. A generic applicant may use different inactive ingredients if the product satisfies applicable pharmaceutical equivalence, bioequivalence, quality, safety, and labeling requirements. The substitution must not compromise dissolution, dose uniformity, stability, or administration performance.

Is LYVISPAH suitable for feeding-tube administration?

The product’s oral administration instructions do not automatically establish feeding-tube compatibility. Tube use requires product-specific testing for recovery, obstruction, adsorption, flushing, and dose delivery.

What is the main technical weakness of a simple mannitol-based baclofen granule?

The principal risks are inadequate bitterness control, powder segregation, moisture sensitivity, and inconsistent packet filling. These risks increase with higher-strength granules and direct-to-mouth administration.

Could a new LYVISPAH version qualify for 505(b)(2) approval?

A materially different baclofen dosage form, delivery system, or formulation could potentially use a 505(b)(2) pathway if the applicant can rely partly on existing findings and supplies appropriate bridging data. The pathway would depend on the extent of formulation and clinical differences.

Which excipient technology offers the greatest licensing value?

Taste-masking technology has the clearest potential value because baclofen bitterness directly affects adherence and patient acceptance. A platform that preserves rapid release while improving taste could support pediatric, dysphagia, and specialty-care products.

References

1. DailyMed. (n.d.). LYVISPAH- baclofen oral granules prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2016). General clinical pharmacology considerations for pediatric studies for drugs and biological products.
3. U.S. Food and Drug Administration. (2021). LYVISPAH NDA 215039 approval information.
4. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the patent and exclusivity provisions.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.